Clearance of MRD. (A-C) Absolute changes in the level of MRD in peripheral blood, as assessed by ASO-qPCR, in 32 patients who had data that could be evaluated from cohorts A (n = 6), B (n = 14), and C (n = 12), as indicated. Therapy time points C3 (end of cycle 3) and C6 (end of cycle 6) of ibrutinib, obinutuzumab, and venetoclax are shown. MRD levels that are detectable, but not quantifiable, are shown as positive nonquantifiable (PNQ). The threshold for MRD negativity in the blood varied according to the sample. Neg, negative values.